Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash-to-Debt 1.67
ARRY's Cash-to-Debt is ranked lower than
73% of the 864 Companies
in the Global Biotechnology industry.

( Industry Median: 53.59 vs. ARRY: 1.67 )
Ranked among companies with meaningful Cash-to-Debt only.
ARRY' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.49  Med: 1.69 Max: No Debt
Current: 1.67
Equity-to-Asset 0.19
ARRY's Equity-to-Asset is ranked lower than
86% of the 635 Companies
in the Global Biotechnology industry.

( Industry Median: 0.65 vs. ARRY: 0.19 )
Ranked among companies with meaningful Equity-to-Asset only.
ARRY' s Equity-to-Asset Range Over the Past 10 Years
Min: -1.55  Med: 0.22 Max: 0.93
Current: 0.19
-1.55
0.93
Piotroski F-Score: 4
Altman Z-Score: 0.41
Beneish M-Score: -2.90
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating Margin % -50.65
ARRY's Operating Margin % is ranked higher than
57% of the 661 Companies
in the Global Biotechnology industry.

( Industry Median: -97.80 vs. ARRY: -50.65 )
Ranked among companies with meaningful Operating Margin % only.
ARRY' s Operating Margin % Range Over the Past 10 Years
Min: -410.11  Med: -89.25 Max: 6.34
Current: -50.65
-410.11
6.34
Net Margin % -58.57
ARRY's Net Margin % is ranked higher than
55% of the 661 Companies
in the Global Biotechnology industry.

( Industry Median: -83.37 vs. ARRY: -58.57 )
Ranked among companies with meaningful Net Margin % only.
ARRY' s Net Margin % Range Over the Past 10 Years
Min: -511.63  Med: -116.55 Max: 18.05
Current: -58.57
-511.63
18.05
ROA % -49.60
ARRY's ROA % is ranked lower than
63% of the 870 Companies
in the Global Biotechnology industry.

( Industry Median: -33.51 vs. ARRY: -49.60 )
Ranked among companies with meaningful ROA % only.
ARRY' s ROA % Range Over the Past 10 Years
Min: -99.03  Med: -50.67 Max: 5.6
Current: -49.6
-99.03
5.6
ROC (Joel Greenblatt) % -701.29
ARRY's ROC (Joel Greenblatt) % is ranked lower than
55% of the 827 Companies
in the Global Biotechnology industry.

( Industry Median: -476.30 vs. ARRY: -701.29 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
ARRY' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -1397.54  Med: -273.72 Max: 297.05
Current: -701.29
-1397.54
297.05
3-Year Revenue Growth Rate 14.30
ARRY's 3-Year Revenue Growth Rate is ranked higher than
65% of the 485 Companies
in the Global Biotechnology industry.

( Industry Median: 4.80 vs. ARRY: 14.30 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
ARRY' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -35.9  Med: -2.7 Max: 39.8
Current: 14.3
-35.9
39.8
3-Year EBITDA Growth Rate 9.40
ARRY's 3-Year EBITDA Growth Rate is ranked higher than
60% of the 515 Companies
in the Global Biotechnology industry.

( Industry Median: 0.20 vs. ARRY: 9.40 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
ARRY' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -66.3  Med: 0.7 Max: 105.1
Current: 9.4
-66.3
105.1
3-Year EPS without NRI Growth Rate 4.50
ARRY's 3-Year EPS without NRI Growth Rate is ranked higher than
58% of the 501 Companies
in the Global Biotechnology industry.

( Industry Median: -2.80 vs. ARRY: 4.50 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
ARRY' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -50.5  Med: 0.7 Max: 55.7
Current: 4.5
-50.5
55.7
GuruFocus has detected 2 Warning Signs with Array BioPharma Inc $ARRY.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» ARRY's 10-Y Financials

Financials (Next Earnings Date: 2017-05-09 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

ARRY Guru Trades in Q1 2016

Ken Fisher 135,695 sh (unchged)
Steven Cohen Sold Out
Paul Tudor Jones Sold Out
Jim Simons 2,154,652 sh (-32.89%)
» More
Q2 2016

ARRY Guru Trades in Q2 2016

Ken Fisher 135,695 sh (unchged)
Jim Simons 17,452 sh (-99.19%)
» More
Q3 2016

ARRY Guru Trades in Q3 2016

Paul Tudor Jones 135,000 sh (New)
Joel Greenblatt 16,705 sh (New)
Jim Simons 424,452 sh (+2332.11%)
Ken Fisher 135,895 sh (+0.15%)
» More
Q4 2016

ARRY Guru Trades in Q4 2016

Steven Cohen 1,570,641 sh (New)
Joel Greenblatt Sold Out
Paul Tudor Jones Sold Out
Jim Simons Sold Out
Ken Fisher 65,693 sh (-51.66%)
» More
» Details

Insider Trades

Latest Guru Trades with ARRY

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:NAS:FGEN, OTCPK:SOLTF, NAS:SRPT, NAS:ONCE, OTCPK:MPSYY, NAS:AAAP, NAS:GBT, NYSE:CBM, NAS:LXRX, NYSE:AXON, OTCPK:DBVTF, NAS:PBYI, NAS:BPMC, NAS:BGNE, NAS:HALO, NAS:DERM, NAS:TBPH, NAS:INVA, OTCPK:GENSF, OTCPK:AKBLF » details
Traded in other countries:AR2.Germany,
Array BioPharma Inc is a biopharmaceutical company. It is engaged in the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer and inflammatory diseases.

Array BioPharma Inc was incorporated in Delaware on February 6, 1998. It is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer and inflammatory diseases. The Company's proprietary drug development pipeline includes clinical candidates that are designed to regulate therapeutically important target pathways. In addition, pharmaceutical and biotechnology companies partner with the Company to discover and develop drug candidates across various therapeutic areas. The Company's proprietary clinical programs include three cancer drugs, binimetinib (MEK162 / wholly-owned), encorafenib (LGX818 / wholly-owned) and selumetinib (partnered with AstraZeneca. The Company's internal drug discovery programs include inhibitors that target Trk receptors for the treatment of oncology and other indications. The Company competes with companies that are engaged in the research and discovery, licensing, development and commercialization of drug candidates, including large pharmaceutical companies with internal discovery and development functions, biotech companies with competing products in the therapeutic areas it is targeting and contract research organizations that perform many of the functions it performs under its collaborations. The Company is subject to substantial regulation by governmental agencies in the U.S. and other countries.

Ratios

vs
industry
vs
history
PB Ratio 30.21
ARRY's PB Ratio is ranked lower than
95% of the 1091 Companies
in the Global Biotechnology industry.

( Industry Median: 3.76 vs. ARRY: 30.21 )
Ranked among companies with meaningful PB Ratio only.
ARRY' s PB Ratio Range Over the Past 10 Years
Min: 3.34  Med: 10.27 Max: 107.8
Current: 30.21
3.34
107.8
PS Ratio 8.17
ARRY's PS Ratio is ranked higher than
62% of the 854 Companies
in the Global Biotechnology industry.

( Industry Median: 12.99 vs. ARRY: 8.17 )
Ranked among companies with meaningful PS Ratio only.
ARRY' s PS Ratio Range Over the Past 10 Years
Min: 1.43  Med: 7.09 Max: 24.26
Current: 8.17
1.43
24.26
Current Ratio 4.10
ARRY's Current Ratio is ranked higher than
51% of the 838 Companies
in the Global Biotechnology industry.

( Industry Median: 4.03 vs. ARRY: 4.10 )
Ranked among companies with meaningful Current Ratio only.
ARRY' s Current Ratio Range Over the Past 10 Years
Min: 0.81  Med: 2.95 Max: 7.86
Current: 4.1
0.81
7.86
Quick Ratio 4.10
ARRY's Quick Ratio is ranked higher than
53% of the 838 Companies
in the Global Biotechnology industry.

( Industry Median: 3.74 vs. ARRY: 4.10 )
Ranked among companies with meaningful Quick Ratio only.
ARRY' s Quick Ratio Range Over the Past 10 Years
Min: 0.81  Med: 2.94 Max: 7.55
Current: 4.1
0.81
7.55
Days Sales Outstanding 92.56
ARRY's Days Sales Outstanding is ranked lower than
69% of the 535 Companies
in the Global Biotechnology industry.

( Industry Median: 59.11 vs. ARRY: 92.56 )
Ranked among companies with meaningful Days Sales Outstanding only.
ARRY' s Days Sales Outstanding Range Over the Past 10 Years
Min: 2.06  Med: 47.09 Max: 497.21
Current: 92.56
2.06
497.21
Days Payable 80.78
ARRY's Days Payable is ranked higher than
60% of the 353 Companies
in the Global Biotechnology industry.

( Industry Median: 58.37 vs. ARRY: 80.78 )
Ranked among companies with meaningful Days Payable only.
ARRY' s Days Payable Range Over the Past 10 Years
Min: 37.58  Med: 76.12 Max: 159.87
Current: 80.78
37.58
159.87

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -7.10
ARRY's 3-Year Average Share Buyback Ratio is ranked higher than
65% of the 563 Companies
in the Global Biotechnology industry.

( Industry Median: -10.90 vs. ARRY: -7.10 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
ARRY' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -111.3  Med: -11.8 Max: -4.2
Current: -7.1
-111.3
-4.2

Valuation & Return

vs
industry
vs
history
Price-to-Net-Current-Asset-Value 35.77
ARRY's Price-to-Net-Current-Asset-Value is ranked lower than
92% of the 870 Companies
in the Global Biotechnology industry.

( Industry Median: 5.79 vs. ARRY: 35.77 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
ARRY' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 2.24  Med: 5.66 Max: 48.85
Current: 35.77
2.24
48.85
Price-to-Tangible-Book 30.00
ARRY's Price-to-Tangible-Book is ranked lower than
94% of the 1017 Companies
in the Global Biotechnology industry.

( Industry Median: 4.44 vs. ARRY: 30.00 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
ARRY' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 1.14  Med: 4.21 Max: 102.93
Current: 30
1.14
102.93
Price-to-Median-PS-Value 1.15
ARRY's Price-to-Median-PS-Value is ranked lower than
61% of the 750 Companies
in the Global Biotechnology industry.

( Industry Median: 1.02 vs. ARRY: 1.15 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
ARRY' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.2  Med: 0.91 Max: 3.1
Current: 1.15
0.2
3.1
Earnings Yield (Greenblatt) % -5.93
ARRY's Earnings Yield (Greenblatt) % is ranked higher than
56% of the 1273 Companies
in the Global Biotechnology industry.

( Industry Median: -8.24 vs. ARRY: -5.93 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
ARRY' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -5.99  Med: 2.25 Max: 5.1
Current: -5.93
-5.99
5.1

More Statistics

Revenue (TTM) (Mil) $170.0
EPS (TTM) $ -0.68
Beta1.64
Short Percentage of Float15.07%
52-Week Range $2.60 - 13.40
Shares Outstanding (Mil)169.01
» More Articles for ARRY

Headlines

Articles On GuruFocus.com
Screen: Stocks With Estimated Revenue Up 5% - January Jan 18 2016 
Insider Buys Round-up: Tenet Healthcare and Sprint Corp Aug 14 2015 
Novartis Gets FTC Nod To Buyout Glaxo Smithkline’s Cancer Drugs Feb 25 2015 
Can These Three BioTech Companies Make It Big? Feb 20 2015 
Array BioPharma Inc. (ARRY) CFO Michael Carruthers sells 1,310 Shares Mar 16 2011 
Array BioPharma Inc. (ARRY) CFO Michael Carruthers sells 1,403 Shares Feb 11 2011 
Array BioPharma Inc. (ARRY) CFO Michael Carruthers sells 1,272 Shares Jan 13 2011 
Array BioPharma Inc. (ARRY) CFO Michael Carruthers sells 1,256 Shares Dec 10 2010 
Array BioPharma Inc. (ARRY) CFO Michael Carruthers sells 1,220 Shares Nov 12 2010 
Array BioPharma Inc. (ARRY) CFO Michael Carruthers sells 1,225 Shares Oct 13 2010 

More From Other Websites
Array BioPharma's NDA for Cancer Drug Withdrawn; Shares Down Mar 22 2017
How to Trade Monday's Most Active Stocks - AMD, Esperion Therapeutics, Nokia and More Mar 20 2017
Array Biopharma Withdraws Cancer Drug Application Mar 20 2017
Apple, Array Biopharma, Alaska Air, and More: Here’s Why These Five Stocks Are in the Spotlight Mar 20 2017
Biotech Premarket Movers: CytomX, Aevi, Esperion Mar 20 2017
Array BioPharma Provides NEMO Update Mar 19 2017
Today's Research Reports on Stocks to Watch: Array Biopharma and Corcept Therapeutics Mar 17 2017
Array BioPharma, Inc. breached its 50 day moving average in a Bearish Manner : ARRY-US : March 16,... Mar 16 2017
Biotech and Pharmaceutical Stocks Fall on Pricing Concerns: Today's Research Reports on Ocera... Mar 09 2017
Array BioPharma To Present At The Cowen And Company Annual Healthcare Conference Mar 01 2017
Biotech Industry Positioned for a Potential Breakout in 2017: Today's Reports on Array Biopharma and... Feb 17 2017
ETFs with exposure to Array BioPharma, Inc. : February 14, 2017 Feb 14 2017
ARRAY BIOPHARMA INC Financials Feb 14 2017
Array BioPharma, Inc. :ARRY-US: Earnings Analysis: Q2, 2017 By the Numbers : February 13, 2017 Feb 13 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)